The information about how DNA sequence varies across the human genome is crucial for unravelling the genetic basis of drug response. A haplotype map, or HapMap, intended to reveal such a variation pattern, has been recently developed by the International HapMap Consortium. Here, we present a conceptual model for directly characterizing specific DNA sequence variants that are responsible for drug response based on the haplotype structure provided by HapMap. Our model is developed in the maximum likelihood context, incorporated by clinically meaningful mathematical functions that model drug response and implemented with the EM algorithm. Our model is employed to a pharmacogenetic study of cardiovascular disease with 107 patients. We found that the haplotype constituted by allele Gly16 (G) at codon 16 and allele Glu27 (G) at codon 27 genotyped within the b2AR candidate gene exhibits a different effect on heart rate curve from the rest haplotypes. Parents with the diplotype consisting of two copies of haplotype GG are more sensitive in heart rate to increasing dosages of dobutamine than those with other haplotypes. This model provides a powerful tool for elucidating the genetic variants of drug response and ultimately designing personalized medications based on each patient's genetic constitution.
INTRODUCTION
Although pharmacogenetics or pharmacogenomics, the study of inherited variation in patients' responses to drugs, is still in its infancy, tremendous accumulation of data for genetic markers and pharmacodynamic tests have made it one of the hottest and most promising areas in biomedical science. [1] [2] [3] [4] [5] [6] [7] [8] The central theme of pharmacogenetics is to associate in-terpatient variability in drug response with specific genomic sites with the aid of powerful statistical tools. Traditional approaches for such association studies are based on the statistical inference of putative genetic loci or quantitative trait loci (QTL) of interest to a phenotype from known linkage or linkage disequilibrium maps. 9, 10 With the completion of a haplotype map (HapMap) constructed from DNA sequence variation data, [11] [12] [13] it has now become possible to characterize concrete nucleotide combinations that encode a complex trait.
Liu et al 14 derived a new statistical method for elucidating DNA sequence variation in complex diseases from HapMap. Compared to complex diseases, genes for drug response are relatively simpler and genetically easier to study because diseases have undergone a long evolutionary pressure, whereas the use of particular drugs is much more recent. However, drug response is statistically more difficult to analyze because it is a dynamic process and should be quantified across multiple different levels of drug concentration or dosage and during a time course. Statistical modelling of such longitudinal traits has been a challenging issue given the complexities of their autocorrelation structure. More recently, an innovative theoretical framework has been constructed within which clinically meaningful pharmacodynamic models are incorporated into the context of genetic mapping for drug response. 15 The basic tenet of this framework is the mathematical modelling of dosage-dependent drug effects that are influenced by genetic determinants and environmental factors and their interactions. The framework does not only display many statistical advantages, such as more power and greater estimation precision, due to a reduced number of unknown parameters, but also is biologically or clinically more relevant given its close annotation to fundamental pharmacological principles.
Here, we present a novel statistical model for determining specific DNA sequences that are associated with the phenotypic variation of drug response. This model is derived on the basis of multilocus haplotype analysis using a finite number of tag single-nucleotide polymorphisms (SNPs). We derived a closed-form solution for estimating the effects of haplotypes, haplotype frequencies, allele frequencies and the degrees of LD of various orders among tag SNPs underlying the response to drugs. We performed simulation studies to test the statistical behaviors of this haplotypebased sequence mapping model. A worked example is used to validate our model, in which a DNA sequence variant is detected to significantly affect the shape of the heart rate curve in response to different dosages of dobutamine.
THEORY

Notation
Suppose there is a random sample drawn from a natural human population at Hardy-Weinberg equilibrium. In this sample, a number of SNPs are genotyped genomewide, aimed to identify DNA sequences responsible for complex diseases or drug response. Recent studies have shown that the human genome has a haplotype block structure, [16] [17] [18] such that it can be divided into discrete blocks of limited haplotype diversity. In each block, a small fraction of SNPs, referred to as 'tag SNPs', can be used to distinguish a large fraction of the haplotypes. Consider R (R41) tag SNPs for a haplotype block. Each of these R SNPs has two alleles denoted by A r kr (k r ¼ 1, 2; r ¼ 1, y, R), with allele frequencies denoted by p ðrÞ kr for the rth SNP. We use superscripts and subscripts to distinguish between different SNPs and different alleles within SNPs, respectively. These SNPs form 2 R possible haplotypes expressed as A 
We intend to associate diplotypes with interpatient variation in drug response based on observed drug responses measured at different dosages (y) and SNP genotypes (G). Generally speaking, a given two-SNP genotype, A 
where X p is contained within the mixture proportion,
and X q is a set of quantitative genetic parameters that specify the multivariate normal distribution, f, including diplotype-specific parameters, that is, phenotypic means of two different diplotypes at different dosages ðu ½k1k2½l1l2 and u ½k1l2½l1k2 Þ, and parameters common to both diplotypes, that is, the (co)variance matrix among dosages ( P ). Suppose there is a particular haplotype, A 1 k1 A 2 k2 , labelled by A, which is different from the other three haplotypes, collectively labelled by a, in its effect on drug response. The resultant diplotypes are thus equivalent to three composite genotypes AA, Aa and aa. The phenotypic mean of each of these three composite genotypes that contains the two distinct groups of haplotypes is denoted as u j for composite genotype j (j ¼ 2 for AA, 1 for Aa and 0 for aa). Considering drug response, each u j at different concentrations can be fit by a clinically meaningful pharmacodynamic model, such as the E max model, that specifies the relationship between drug concentration (C) and drug effect (E) 20 based on
where E 0j is the constant or baseline value for the drug response parameter, E maxj is the asymptotic (limiting) effect, EC 50j is the drug concentration that results in 50% of the maximal effect, and H j is the slope parameter that determines the slope of the concentration-response curve. The larger the H, the steeper the linear phase of the the logconcentration-effect curve. By estimating these curve parameters separately for different genotypes, we can determine how the DNA sequence variants influence drug response based on the shape differences among the three curves. As a longitudinal trait, the (co)variance matrix of drug response can be structured by many statistical models, such as the first-order autoregressive [AR(1)] model, 15 which states that the variance (s 2 ) is constant over different concentrations, and that the correlation of response between different concentrations decreases proportionally (in r) with increased concentration interval.
Assuming that haplotype A 1 1 A 1 2 is different from the rest haplotypes (Table 1) , the log-likelihood function can be expanded to include all possible SNP genotypes, which is now expressed as
where unknown vector X q now contains the curve and matrix-structuring parameters, arrayed by (E 0j , E max-
An Integrative EM Algorithm
We derived a closed-form solution for estimating the unknown parameters with the EM algorithm. Haplotype n n n n n n n n where D is the linkage disequilibrium between the two SNPs. Thus, once haplotype frequencies are estimated, we can estimate allelic frequencies and LD by solving equation (5) . The estimates of haplotype frequencies are based on the loglikelihood function of equation (1), whereas the estimates of diplotype curve parameters and (co)variance-structuring parameters are based on the log-likelihood function of equation (4). These two different types of parameters can be estimated using an integrative EM-simplex algorithm.
In the E step, the expected number ( Note that for all the other genotypes, such probabilities do not exist.
In the M step, the probabilities calculated in the previous iteration are used to estimate the haplotype frequencies usingp
2n These estimated frequencies are embedded to the M step for estimating X q derived from the simplex algorithm. 21 Iterations including the E and M steps are repeated until the estimates of the parameters converge to stable values. The sampling errors of these parameters can be estimated by calculating Louis' observed information matrix. 22 
Hypothesis Tests
We can test two major hypotheses in the following sequence: (1) the association between two SNPs by testing their LD, and (2) the difference of a given haplotype from the rest haplotypes in its effect on drug response. The LD between two given SNPs can be tested using two alternative hypotheses:
The log-likelihood ratio test statistic for the significance of LD is calculated by comparing the likelihood values under H 1 (full model) and H 0 (reduced model) using
The log-likelihood ratio test statistic (LR 2 ) under these two hypotheses can be similarly calculated. The LR 2 may asymptotically follow a w 2 distribution with eight degrees of freedom. However, the approximation of a w 2 distribution may be inappropriate when some regularity conditions are violated. The permutation test approach does not rely upon the distribution of the LR 2 , and may be used to determine the critical threshold for determining the effect of DNA sequence variation on drug response.
R-SNP Sequence Model
The idea for sequencing drug response based on a two-SNP model can be extended to include an arbitrary number of SNPs whose sequences are associated with the phenotypic variation. Consider R SNPs that form 3 R observable multilocus zygotic genotypes, generally expressed as A In the multi-SNP sequencing model, we face many haplotypes and haplotype pairs. An AIC-based model selection strategy has been framed to determine the haplotype that is most distinct from the rest of the haplotypes in explaining quantitative variation.
APPLICATION
A real example for a genetic study of cardiovascular disease is used to demonstrate the usefulness of our model. Cardiovascular disease, principally heart disease and stroke, is the leading killer for both men and women among all racial and ethnic groups. Dobutamine is a medication that is used to treat congestive heart failure by increasing heart rate Drug response with HapMap M Lin et al and cardiac contractility, with actions on the heart similar to the effect of exercise. Dobutamine is also commonly used to screen for heart disease in those unable to perform an exercise stress test. It is this latter use for which the study participants received dobutamine in this study. It is a synthetic catecholamine that primarily stimulates b-adrenergic receptors (bAR), which play an important role in cardiovascular function and responses to drugs. [23] [24] [25] Both the b1AR and b2AR genes have several polymorphisms that are common in the population. Two common polymorphisms are located at codons 49 (Ser49Gly) and 389 (Arg389Gly) for the b1AR gene and at codons 16 (Arg16Gly) and 27 (Gln27Glu) for the b2AR gene. 24 The polymorphisms in each of these two receptor genes are in linkage disequilibrium, which suggests the importance of taking into account haplotypes, rather than a single polymorphism, when defining biologic function. This study attempts to detect haplotype variants within these candidate genes, which determine the response of heart rate to varying concentrations of dobutamine.
A group of 163 men and women in ages from 32 to 86 years participated in this study. Patients had a wide range of testing (untreated) heart rate. Each of these subjects was genotyped for SNP markers at codons 49 and 389 within the b1AR gene and at codons 16 and 27 within the b2AR gene. Dobutamine was injected into these subjects to investigate their response in heart rate to this drug. The subjects received increasing doses of dobutamine, until they achieved target heart rate response or predetermined maximum dose. The dose levels used were 0 (baseline), 5, 10, 20, 30 and 40 mcg min, at each of which heart rate was measured. The time interval of 3 min is allowed between two successive doses for subjects to reach a plateau in response to that dose. Only those (107) in whom there were heart rate data at all the six dose levels were included for data analyses.
By assuming that one haplotype is different from the rest of the haplotypes, we hope to detect a particular DNA sequence associated with the response of heart rate to dobutamine. The phenotypic data for drug response were normalized as percentages to remove the baseline effect, which is due to between-subject differences in heart rate prior to the test. At the b1AR gene, we did not find any haplotype that contributed to interindividual difference in heart rate response. A significant effect was observed for haplotype Gly16(G)-Glu27(G) within the b2AR gene ( Table 2 ). The log-likelihood ratio (LR) test statistics based on equation (14) for the difference of GG from the other three haplotypes was 30.03, which is significant at P ¼ 0.021 based on the critical threshold determined from 1000 permutation tests. The LR values when selecting any haplotype rather than GG as a reference gave no significant results (P ¼ 0.16-0.40). We used a second testing criterion based on the area under curve (AUC) to test the haplotype effect. This test supports the result from the first test.
The maximum likelihood estimates (MLEs) of the population genetic parameters, such as haplotype frequencies, allele frequencies and linkage disequilibrium between the two SNPs, within the b2AR gene were obtained from our model. As indicated by the sampling errors of the MLEs based on Louis' (1982) approach, these estimates display reasonable precision. The allele frequencies within this gene are estimated as 0.62 for Gly16 at codon 16 and 0.40 for Glu27 at codon 27. The MLE of the linkage disequilibrium between the two SNPs is 0.1303. These suggest that the two SNPs identified within the b2AR gene display a pretty high heterozygosity and linkage disequilibrium.
The MLEs of the quantitative genetic parameters were obtained, also with reasonable estimation precision ( Table  2 ). Using the estimated response parameters, we drew the profiles of heart rate response to increasing dose levels of dobutamine for three composite genotypes comprising of haplotypes GG and non-GG (symbolized by GG) (Figure 1) . The composite homozygote [GG] [GG] displayed consistently higher heart rate across all dose levels, especially at dose levels higher than the composite homozygote ½GG½GG. But the composite heterozygote had consistently the lowest curve at all dose levels tested. We used AUC to test in which gene action mode (additive or dominant) haplotypes affect drug response curves for heart rate. The testing results suggest that both additive and dominant effects are important in determining the shape of the response curve (Table 3) , together accounting for about 14% of the observed variation in drug response. We did not detect evidence for haplotypes to have an effect on curve parameters, H and EC 50 , for the heart rate response.
We performed simulation studies to investigate the statistical properties of our model. The data were simulated by mimicking the example used above in order to determine the reliability of our estimates in this real application. One haplotype was assumed to be different from the other three. The data simulated under this assumption were subject to statistical analyses, pretending that haplotype distinction is unknown. As expected, only under the correct haplotype distinction could the haplotype effect be detected and the parameters be accurately and precisely estimated (Table 4) .
DISCUSSION
SNPs have been powerful to study the structure and organization of the human genome. [16] [17] [18] A recently developed HapMap 11 will provide an invaluable tool to understand the structure, organization and function of the human genome. The understanding of the first two aspects has been less problematic in part because fewer statistics are used, but the association between specific genomic sites and disease risk or drug response has been a pressing challenge in current pharmacogenetic and pharmacogenomic studies. The model presented here, aimed to detect specific DNA sequence variants for drug response, should represent a timely effort to accelerate the research toward the identification of genes of interest.
Our model is founded on the discovery of tag SNPs in the genome, thus allowing for a fast scan for the association between variation in DNA sequence and traits. [16] [17] [18] This model has three advantages. First, it can materialize the genetic basis for quantitative variation by directly characterizing Drug response with HapMap M Lin et al specific DNA sequences predisposing to drug response. The traditional statistical models for genetic mapping attempt to postulate the position of hypothesized QTL that are linked with known markers genotyped from the genome. The QTL detected from these models are regarded as 'hypothesized' because it is not possible to know their DNA sequences and, therefore, physiological function. As opposed to the traditional 'indirect' approach, our model presents a 'direct' approach. At present, the utility of the direct approach is limited to sequencing the functional parts of candidate genes with known biochemical or physiological function. With the release of HapMap, our model will make the direct Figure 1 Profiles of heart rate in response to different dosages of dobutamine (indicated by dots) for three composite genotypes (foreground) identified at two SNPs within the b2AR gene. The profiles of 107 studied subjects from which the three different composite genotypes were detected are also shown (background). The asymptotic sampling errors of the MLEs are given in the parantheses. The LR 1 tests for the significance of haplotype effect based on hypothesis (14) . The optimal haplotype model detected on the basis of the LR test is indicated in boldface. There are two alleles Arg16 (A) and Gly16 (G) at codon 16 and two alleles Glu27 (C) and Glu27 (G) at codon 27.
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M Lin et al approach more useful and more efficient in search for causal variants throughout the whole genome. Second, our model is statistically simple and computationally fast. The most difficult part for the estimation from our model is to construct diplotype configurations for heterozygous genotypes at two or more SNPs. The estimation of population genetic parameters is based on a multinomial likelihood function of the observed genotype data, whereas the estimation of quantitative genetic parameters is based on a mixture-based likelihood function including different diplotypes. These two likelihood functions can be easily integrated to a unified estimation framework implemented with the EM algorithm. Finally, our model is robust and flexible to different genetic and experimental settings. The results from a simulation study indicate that the association between DNA sequence and phenotype can be well detected when the trait has a modest heritability level (0.14) or a modest sample size (107) is used. Our model can also obtain fairly precise estimation of parameters when diplotypes display overdominance in the situation with modest heritability and sample size. The specific utility of our model to a real example from a genetic study leads to the successful detection of a DNA sequence (haplotype) at codons 16 and 27 genotyped within the b2AR candidate gene for its significant impact on response in heart rate to dobutamine. This haplotype, composed of the Gly16 form of codon 16 and the Glu27 form of codon 27, tends to increase heart rate when it is combined with itself or any other haplotypes, and account for about 14% of the total observed variation in drug response.
Although our simulation and example were based on 2-SNP analyses, our sequencing model has been developed to allow for the detection of sequence variants involving any number of SNPs within a haplotype block. In addition to its use in studying genetic associations in natural populations, our sequencing model can be extended to study the genetic factors contributing to variation in drug response in controlled crosses such as the backcross or F 2 as used in mouse. It can also be modified to estimate the effects of sequence-sequence interaction on drug response. It is possible that a haplotype within a candidate gene interacts with haplotypes from other candidate genes. The characterization of specific DNA sequence variants for drug response should allow the development of tests to predict which drugs or vaccines would be most effective in individuals with particular genotypes for genes affecting drug metabolism. The numbers in parentheses are the squared roots of the mean square errors of the MLEs based on 1000 simulation replicates. The correct haplotype model and the corresponding estimates are indicated in boldface.
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